Search results for " portal vein"

showing 10 items of 11 documents

Pattern of macrovascular invasion in hepatocellular carcinoma

2021

Background and aims: In patients with hepatocellular carcinoma (HCC), macrovascular invasion (MaVI) limits treatment options and decreases survival. Detailed data on the relationship between MaVI extension and patients' characteristics, and its impact on patients' outcome are limited. We evaluated the prevalence and extension of MaVI in a large cohort of consecutive HCC patients, analysing its association with liver disease and tumour characteristics, as well as with treatments performed and patients' survival. Methods: We analysed data of 4774 patients diagnosed with HCC recorded in the Italian Liver Cancer (ITA.LI.CA) database (2008-2018). Recursive partition analysis (RPA) was performed …

Ablation TechniquesMaleRegistrieCirrhosisClinical BiochemistryMesenteric Veinloco-regional treatment030204 cardiovascular system & hematologyBiochemistryGastroenterologysurgeryAntineoplastic AgentLiver disease0302 clinical medicineNon-alcoholic Fatty Liver Diseasecirrhosis; hepatocellular carcinoma; loco-regional treatment; portal vein thrombosis; surgery; transplantationAscitesAblation Techniqueportal vein thrombosisRegistries030212 general & internal medicineChronicSettore MED/12 - GastroenterologiaPortal VeinLiver DiseasesLiver NeoplasmsAsciteshepatocellular carcinomaGeneral MedicineMiddle AgedSorafenibPrognosisHepatitis BAlcoholicHepatitis CTumor BurdenSurvival RateItalyLiver NeoplasmHepatocellular carcinomaAsciteFemalemedicine.symptomLiver cancerHumanmedicine.medical_specialtyCarcinoma HepatocellularPrognosiAntineoplastic AgentsEnd Stage Liver Disease03 medical and health sciencesMesenteric VeinsHepatitis B ChronicInternal medicinemedicineHumansHepatectomyNeoplasm Invasivenessportal vein thrombosiLiver Diseases AlcoholicAgedNeoplasm Invasivene...Performance statusbusiness.industrycirrhosisCarcinomaSettore MED/09 - MEDICINA INTERNAPatient AcuityHepatocellularHepatitis C Chronicmedicine.diseaseLiver TransplantationTransplantationLiver functionbusinesscirrhositransplantationEuropean Journal of Clinical Investigation
researchProduct

Focal nodular hyperplasia-like lesions in patients with cavernous transformation of the portal vein: prevalence, MR findings and natural history.

2011

PURPOSE: To retrospectively investigate the prevalence, MR findings, natural history, and association with other hepatic lesions of focal nodular hyperplasia (FNH)-like lesions in a cohort of consecutive patients with cavernous transformation of the portal vein (CTPV). MATERIALS AND METHODS: This retrospective IRB-approved study comprised 58 patients (32 men, 26 women; average age, 50 years) with CTPV who underwent liver MR imaging between 2000 and 2008. MR images were assessed by two radiologists in consensus for the presence of (a) FNH-like lesions and other liver lesions, and (b) other imaging findings. Patients were assigned to a stable or progressive clinical course based on lesion cha…

AdultMalemedicine.medical_specialtyAbdomen Liver Cavernous transformation of the portal vein Benign liver neoplasms Magnetic resonance imagingAdenomaLesionHemangiomaCohort StudiesReference ValuesmedicineImage Processing Computer-AssistedHumansRadiology Nuclear Medicine and imagingLiver focal nodular hyperplasia cavernomatosis portal veinNeuroradiologyAgedRetrospective Studiesmedicine.diagnostic_testbusiness.industryPortal VeinLiver NeoplasmsFocal nodular hyperplasiaMagnetic resonance imagingInterventional radiologyGeneral MedicineMiddle Agedmedicine.diseaseMagnetic Resonance Imagingmedicine.anatomical_structureTreatment OutcomeFocal Nodular HyperplasiaAbdomenFemaleRadiologymedicine.symptombusinessSettore MED/36 - Diagnostica Per Immagini E RadioterapiaEuropean radiology
researchProduct

Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: The more, the worse?

2018

BACKGROUND & AIMS Portal vein tumour thrombosis (PVTT) has a significant impact on the prognosis of patients with hepatocellular carcinoma (HCC). The degree of PVTT varies from sub-/segmental invasion to complete occlusion of the main trunk. Aim of this study was to evaluate whether the degree of PVTT correlates with prognosis. METHODS A total of 1317 patients with HCC treated at our tertiary referral centre between January 2005 and December 2016 were included. PVTT was diagnosed by contrast-enhanced computed tomography or magnetic resonance imaging. The extent of PVTT was documented according to the Liver Cancer Study Group of Japan classification: Vp0 = no PVTT, Vp1 = segmental portal vei…

AdultMalemedicine.medical_specialtyCarcinoma HepatocellularAdolescentvirusesPortal veinYoung Adult03 medical and health sciences0302 clinical medicineGermanyComplete occlusionHepatectomyHumansMedicineIn patientAgedRetrospective StudiesAged 80 and overVenous ThrombosisHepatologyLeft portal veinmedicine.diagnostic_testPortal Veinbusiness.industryLiver NeoplasmsMagnetic resonance imagingMiddle AgedPrognosismedicine.diseaseSurvival AnalysisThrombosisSurvival Rate030220 oncology & carcinogenesisHepatocellular carcinomaFemale030211 gastroenterology & hepatologyRadiologybusinessLiver cancerLiver International
researchProduct

Portal vein thrombosis and Budd-Chiari syndrome as onset of polycythemia vera

2013

Budd-Chiari syndrome may be defined as a heterogeneous group of vascular disorders characterized by obstruction of hepatic venous return to the level of hepatic venules, supra-hepatic veins, inferior vena cava or right atrium. The main cause of this syndrome is represented by myeloproliferative diseases and, in particular, by polycythemia vera. The latter may cause multiple splanchnic thrombosis, including portal vein thrombosis, particularly important for its clinical outcomes (ascites, collateral vessels genesis, etc.). We report 2 cases of a Budd-Chiari syndrome induced by polycythemia vera characterized by an abnormal clinical onset, both as regards subjects’ age (29 and 39 years old, r…

Budd-Chiari syndromemedicine.medical_specialtySettore MED/09 - Medicina Internalcsh:MedicineInferior vena cavaPolycythemia verapolycythemia verahemic and lymphatic diseasesAscitesmedicinePortal vein thrombosibusiness.industrylcsh:RGeneral Medicinemedicine.diseaseThrombosisSurgeryPortal vein thrombosisBudd-Chiari syndrome portal vein thrombosis myeloproliferative disease polycythemia vera.medicine.veinPortal vein thrombosis; Budd-Chiari syndrome; polycythemia vera;Budd–Chiari syndromemedicine.symptomSplanchnicbusinessVenous return curve
researchProduct

Circulating Endothelial Cell Levels Correlate with Treatment Outcomes of Splanchnic Vein Thrombosis in Patients with Chronic Myeloproliferative Neopl…

2022

Circulating endothelial cells (CECs) are viable, apoptotic or necrotic cells, identified by CD 146 surface antigen expression, considered a biomarker of thrombotic risk, given their active role in inflammatory, procoagulant and immune processes of the vascular compartment. Growing evidence establishes that CECs are also involved in the pathogenesis of several hematological and solid malignancies. The primary aim of this study was to verify if CEC levels could predict both the course and treatment responses of splanchnic vein thrombosis (SVT), either in patients affected by myeloproliferative neoplasms (MPNs) or liver disease. Thus, a retrospective multicenter study was performed; fifteen pa…

Circulating endothelial cellcardiovascular systemMyeloproliferative neoplasmMedicine (miscellaneous)myeloproliferative neoplasms; portal vein thrombosis; circulating endothelial cells; recanalizationRecanalizationPortal vein thrombosi
researchProduct

Hepatic enhancement in cirrhosis in the portal venous phase: what are the differences between gadoxetate disodium and gadobenate dimeglumine?

2020

Purpose: To compare the level of parenchymal and portal venous enhancement in the portal venous phase (PVP) in cirrhotic patients undergoing gadoxetate disodium- and gadobenate dimeglumine-enhanced MRI. Methods: In this retrospective study, 84 cirrhotic patients (mean age ± SD: 66 ± 13 years) who underwent contrast-enhanced MRI with both gadoxetate disodium and gadobenate dimeglumine between 2012 and 2018 were included. Two readers measured signal intensities of hepatic parenchyma, portal vein and psoas muscle on precontrast and PVP. Relative enhancement (RE), image contrast, and portal vein-to-liver contrast difference were calculated. Intraindividual differences were compared with the Wil…

Gadolinium DTPALiver Cirrhosismedicine.medical_specialtyCirrhosisUrologyPortal veinContrast MediaPortal venous phase030218 nuclear medicine & medical imagingGadoxetate Disodium03 medical and health sciences0302 clinical medicinePrecontrastMeglumineInternal medicineGadobenate dimegluminemedicineOrganometallic CompoundsHumansRadiology Nuclear Medicine and imagingGADOBENATE DIMEGLUMINEAgedRetrospective StudiesCirrhosis Portal vein Gadobenate dimeglumine Gadoxetate disodium Hepatic parenchymaHepatic parenchymaRadiological and Ultrasound Technologybusiness.industryGastroenterologyHepatologyMiddle Agedmedicine.diseaseImage EnhancementMagnetic Resonance ImagingCirrhosisHepatic parenchyma030220 oncology & carcinogenesisPortal veinGadoxetate disodiumNuclear medicinebusiness
researchProduct

Imaging-guided interventions modulating portal venous flow: Evidence and controversies

2021

Portal hypertension is defined by an increase in the portosystemic venous gradient. In most cases, increased resistance to portal blood flow is the initial cause of elevated portal pressure. More than 90% of cases of portal hypertension are estimated to be due to advanced chronic liver disease or cirrhosis. Transjugular intrahepatic portosystemic shunts, a non-pharmacological treatment for portal hypertension, involve the placement of a stent between the portal vein and the hepatic vein or inferior vena cava which helps bypass hepatic resistance. Portal hypertension may also be a result of extrahepatic portal vein thrombosis or compression. In these cases, percutaneous portal vein recanalis…

HepatologyGastroenterologyInternal MedicineImmunology and AllergyALPPS associating liver partition and portal vein ligation for staged hepatectomy transjugular intrahepatic portosystemic shunt BSG British Society of Gastroenterology EASL European Association for the Study of the Liver FLR future liver remnant HE hepatic encephalopathy NCBA N-butyl cyanoacrylate PH portal hypertension PVE portal vein embolisation PVR portal vein recanalisation TIPS transjugular intrahepatic portosystemic shunt Portal vein interventions TACE trans-arterial chemoembolization portal vein recanalization RCT randomised controlled trial portal vein embolization portal hypertension image guidedJHEP Reports
researchProduct

Comparison of two different techniques of reperfusion in adult orthotopic liver transplantation

2006

: The aim of this study was to determine the impact of two reperfusion techniques on the peri-operative hemodynamic changes and early post-operative graft function of adult patients undergoing orthotopic liver transplantation. Material and methods: From June 2003 to May 2004, 50 consecutive liver transplants were performed and divided into two groups: group A, 25 patients, portal vein flush with 500 cm3 of Ringer's lactate without vena caval venting. Group B, 25 patients, vena caval venting with no portal vein flush. Donor and recipient characteristics were similar in both groups. Sixty-four different parameters were analyzed, and Pearson's χ2 test and t-test were used for statistical analy…

InferiorAdultMalemedicine.medical_specialtyOrthotopic liver transplantation; Post-reperfusion syndrome; Reperfusion technique; Adolescent; Adult; Aged; Aged 80 and over; Child; Female; Humans; Liver Transplantation; Male; Middle Aged; Portal Vein; Reperfusion; Tissue Donors; Vena Cava Inferior; TransplantationVena CavaAdolescentOrthotopic liver transplantationmedicine.medical_treatmentPortal veinHemodynamicsPost-reperfusion syndromeVena Cava InferiorLiver transplantationVena caval80 and overmedicineHumansStatistical analysisChildAgedAged 80 and overReperfusion techniqueTransplantationAdult patientsPortal Veinbusiness.industrySignificant differenceMiddle AgedSettore ING-IND/35 - Ingegneria Economico-GestionaleTissue DonorsLiver TransplantationSurgerySettore MED/18 - Chirurgia GeneraleReperfusioncardiovascular systemFemaleOrthotopic liver transplantationbusinessClinical Transplantation
researchProduct

Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib

2020

Sorafenib is the first multikinase inhibitor demonstrating a survival benefit for patients suffering from advanced hepatocellular carcinoma (HCC). However, 1 issue remains open: what is the factor able to predict which patients will be long survivors?In the present study, we harnessed the potential of conditional survival, aiming at estimating the probability that a patient receiving sorafenib survives for more than 3 years.The present multicentric study was conducted on a cohort of 438 HCC patients. The primary end point was conditional overall survival. Kaplan-Meier survival analysis was used to calculate conditional overall survival probabilities at 3 years.The 3-year conditional surviva…

macro-vascular portal vein invasionMaleCarcinoma HepatocellularAntineoplastic Agentsextra hepatic disease and BCLCsurvivalNLRAntineoplastic AgentCohort Studiesalpha-fetoproteinHumansLymphocyte CountSurvivorsprognostic factorAgedLiver NeoplasmsMiddle AgedSorafenibProgression-Free SurvivalItalyLiver Neoplasmalpha-fetoprotein; extra hepatic disease and BCLC; hepatitis C; macro-vascular portal vein invasion; NLR; prognostic factor; survivalFemaleCohort Studiehepatitis CCarcinoma Hepatocellular ...Liver Neoplasms ...Human
researchProduct

Very Early Presentation of Extrahepatic Portal Vein Obstruction Causing Portal Hypertension in an Infant: Uncertainties in the Management and Therape…

2016

Extrahepatic portal vein obstruction, although rare in children, is a significant cause of portal hypertension (PHT) leading to life-threatening gastrointestinal bleeding in the pediatric age group. PHT may also lead to other complications such as hyperesplenism, cholangyopathy, ascites, and even hepatopulmonary syndrome and portopulmonary hypertension that may require organ transplantation. Herein we report the case of an asymptomatic 11-month-old infant wherein a hepatomegaly and cavernous transformation of the portal vein was detected by liver ultrasound. Neither signs of thrombosis in arteriovenous system, nor affectation of biliary tract were identified in the magnetic resonance imagin…

medicine.medical_specialtyFollow-up guidelinesPortal venous pressureSingle CaseEsophageal varices03 medical and health sciences0302 clinical medicineEsophageal varicesAscitesmedicinelcsh:RC799-869Hepatopulmonary syndromePortopulmonary hypertensionbusiness.industryGastroenterologyInfantCavernous transformation of portal veinmedicine.diseaseCollateral circulationThrombosisSurgery030220 oncology & carcinogenesisPortal hypertensionlcsh:Diseases of the digestive system. Gastroenterology030211 gastroenterology & hepatologyRadiologymedicine.symptombusinessCase Reports in Gastroenterology
researchProduct